Search clinical trials for: PF-07321332 Dose 4

Total 403 results

Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Withdrawn

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

Healthy Participants
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
SpringWorks Therapeutics, Inc.

Active, not recruiting

Nirogacestat in Ovarian Granulosa Cell Tumors

Ovarian Cancer | Ovarian Granulosa Cell Tumor | Ovarian Granulosa-Stromal Tumor

United States, Canada, Poland
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Pfizer

Completed

Study in Healthy Adults Evaluating PF-07202954

Liver Fibrosis | Non-Alcoholic Fatty Liver Disease

United States
Pfizer

Completed

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Type 2 Diabetes Mellitus

Japan
Pfizer

Completed

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | COPD | Chronic Obstructive Airway Disease

Germany
Pfizer

Completed

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Rutgers, The State University of New Jersey
Centers for Disease Control and Prevention

Completed

Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention

Violence | Helping Behavior | Sexual Assault and Rape | Assaultive Behavior

United States
Pfizer
Trans Tech Pharmaceuticals

Completed

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Alzheimer Disease

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Pfizer

Completed

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

Bioavailability

United States
MicuRx
Worldwide Clinical Trials

Completed

Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4

Safety
Pfizer

Withdrawn

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

Healthy

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
Pfizer

Completed

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

Renal Impairment

United States
Pfizer

Completed

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

COVID-19

United States, Russian Federation, Thailand, Czechia, Colombia, Bulgaria, Japan, South Africa, Turkey, Argentina, Hungary, Malaysia, Mexico, Poland, Spain, Ukraine, Brazil
Pfizer

Completed

6-week Safety and PD Study in Adults With NAFLD

Non-alcoholic Fatty Liver Disease

United States
Pfizer

Completed

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Healthy Subjects

Belgium
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Loyola University
National Cancer Institute (NCI)

Active, not recruiting

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Melanoma

United States
University of Sao Paulo General Hospital

Completed

Impact of Low Dose Fluoroscopy in Ureteroscopy

Ureteral Stone

Brazil
Pfizer
Thrombolysis In Myocardial Infarction (TIMI)

Recruiting

A Study of Ponsegromab in People With Heart Failure (GARDEN TIMI 74)

Heart Failure

United States, Canada, China, Australia, Spain, Japan, Czechia, Hungary, United Kingdom, Poland, Germany
Pfizer

Active, not recruiting

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
University of Maryland, Baltimore
Medical Technology Enterprise Consortium (MTEC)

Completed

Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)

Dengue

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Breast Cancer | Solid Tumors

China, United States, Bulgaria, Spain, Brazil, Czechia, Argentina, South Africa, Mexico
Boehringer Ingelheim

Completed

Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer

Head and Neck Neoplasms
Third Affiliated Hospital, Sun Yat-Sen University

Unknown

Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation

Hepatocellular Carcinoma

China
Aronora, Inc.

Completed

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

Thrombosis

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Gout Arthritis

China
Pfizer

Recruiting

A Study for Two Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

Healthy Participants

United States
Sparrow Pharmaceuticals

Recruiting

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor (ACSPIRE)

Autonomous Cortisol Secretion (ACS) | ACTH-Independent Cushing Syndrome | ACTH-Independent Adrenal Cushing Syndrome, Somatic

United States, United Kingdom, France, Romania
Anagram Therapeutics, Inc.

Recruiting

Phase 1 Study to Assess Safety and Efficacy of ANG003

Exocrine Pancreatic Insufficiency

United States
GlaxoSmithKline

Completed

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

Lung Injury, Acute

United States, Canada
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

China
MedImmune LLC

Completed

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Efficacy and Safety Study in Subjects With Asthma

Asthma

United States
MedImmune LLC

Completed

A Study to Assess the Safety of MEDI7836 in Healthy Adults.

Healthy Adults

United Kingdom
Pfizer

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
Pfizer

Completed

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

Healthy

United States
Pennington Biomedical Research Center
National Center for Complementary and Integrative Health (NCCIH); Office of...

Completed

Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) (RT2)

Diabetes Prevention

United States
Epeius Biotechnologies

Terminated

Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Yale University
National Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaborators

Recruiting

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Early Course Schizophrenia Spectrum Disorder

United States
CK Regeon Inc.

Completed

Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects

Healthy

Korea, Republic of
Bioxodes S.A.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects

Healthy

Belgium
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

Type 2 Diabetes | Healthy Volunteers

United States, Canada
Pulmongene Ltd.

Completed

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015

Idiopathic Pulmonary Fibrosis

Australia
Aronora, Inc.

Completed

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

Thrombosis

United States

3

Subscribe